tbuckley/cabot-search huggingface dataset:
SP0153 Cooperating the baltic states (latvia)
Authors: KA Carselind
Journal: Annals of the Rheumatic Diseases (2001)

<h3></h3> The Swedish Rheumatism Association, SRA, and other organisations for disabled persons have joined together in an association called SHIA. SHIA is part of the Swedish aid organisation SIDA. SIDA provides most of the money for the different projects, that SHIA runs. Of special interest for this conference are the projects concerning the new candidate countries to the European Union in the Baltic states. Many of the organisations within SHIA have their own projects for providing help in different ways, e.g. SRA and organisations concerning diabetes, heart-lungs, asthma-allergy and mentally retarded young people. We all work close together with our "sister-organisations" in the Baltic states. Together we have a project for establishing the UN Standard rules for equal accessibility in Latvia. During the Soviet time many disabled persons were "hidden" and didn't have the possibilities to come together with other or to come out in the fresh air regularly. Many persons still don't have the means we have for daily living and for going out, but things are now changing very quickly for the better. The SRA has, together with the corresponding organisation in Latvia, a project to establish a democratic organisation for, and led by, patients. It all started with some doctors and nurses from Latvia, who came to Stockholm to study rheumatologic care. We met with them and told them about how patient organisations, and SRA in particular, work in Sweden, and it was then decided that SRA should help them to establish a patient organisation in Latvia. We have allowed money in our own budget for this, and we also cooperate with SHIA. I'm sorry to say that SIDA has cut down our allowances, so we have to choose very carefully what we can afford to do! The Latvian organisation, LKLSSB, was founded only three years ago. They now have some hundred members and are represented in eight Latvian regions. They offer a lot of activities for their members: lectures, study groups, excursions etc. They also work with/for young people in their organisation and also cooperate with Unga Reumatiker (Young Rheumatics) in Sweden. Some of our Swedish "ombudsmen" have been in Latvia to help our Latvian friends to establish the organisation, e.g. with list of members, how to run a democratic association, computer-work, how to write/translate and print brochures and booklets, and how to engage media and politicians to help in information and legislation etc. In our common work we have also found, that we have a lot to learn from our Latvian friends. They are not stuck in traditions and old habits, they have new fresh ideas, and as they start "from scratch" they can choose priorities and build up a new society with better possibilities for disabled persons. I have taken part in this project for two years now, and it has made a great impression on me to see the progress and the enthusiasm in the Latvian work!
Beyond <i>BRCA</i>? clinical utility of homologous recombination deficiency in gastrointestinal cancers.
Authors: Erica S Tsang, Veronika Csizmok, Laura Williamson, Erin D. Pleasance, James T. Topham, Joanna Karasinska, Emma Titmuss, Kasmintan A Schrader, Fergus Cafferty, Stephen Yip, Basile Tessier-Cloutier, Karen Mungall, Sophie Sun, Howard John Lim, Jonathan M. Loree, Janessa J. Laskin, Marco A. Marra, Steven J. M. Jones, David F. Schaeffer, Daniel John Renouf
Journal: Journal of Clinical Oncology (2021)

472 Background: There is emerging evidence about the predictive role of homologous recombination deficiency (HRD) in multiple cancers. The clinical utility of HRD is less well defined in gastrointestinal (GI) malignancies. Methods: We reviewed the whole genome (WGS) and transcriptomic (RNA-Seq) data of patients with advanced GI cancers between 2012-2018 in the Personalized Oncogenomics trial (NCT02155621). Scores were calculated as the sum of loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions scores. HRD was defined as a score ≥34. Mutational analysis was performed to determine the presence of mutational signature 3, which is usually strongly associated with BRCA status. Retrospective chart review was conducted to extract treatment and survival outcomes. Overall survival (OS) from initiation of first-line systemic therapy and time to progression on platinum therapy (TTPp) were calculated. Linear and multivariable regression analyses were conducted. Results: Of 154 patients with GI primaries, 56% were male and 105 (68%) were exposed to a platinum agent in the metastatic setting. Primary sites included upper GI (N=20, 9%), pancreas (N=35, 16%), colorectal (N=74, 33%), and other GI primary (N=25, 11%). Ten patients (6%) had a BRCA1/2 mutation, 20 (13%) had a high HRD score, and 11 (7%) had a high signature 3 score (&gt;0.05). Six patients had both high HRD and high signature 3 scores (Table). On linear regression, high HRD scores and mutational signature 3 were independently associated with longer TTPp (β=4.17, 95% CI 0.15-8.19, p=0.04; β=8.03, 95% CI 2.87-13.18, p&lt;0.05, respectively). On multivariable linear regression, after adjusting for HRD score, BRCA1/2 status, and tumor site, only cases with a mutational signature 3 retained significance ( p&lt;0.05). HRD status was not prognostic for OS (HR 1.02, 95% CI 0.65-1.62, p=0.92). Conclusions: Within a cohort of patients with GI malignancies characterized by WGS and RNA-Seq, mutational signature 3 was more strongly associated with TTPp compared to HRD score. These data highlight potential predictive implications of Signature 3 to complement HRD and BRCA status in identifying patients who may benefit from exposure to platinum therapy. [Table: see text]
Modeling sequential systemic therapy for unresectable hepatocellular carcinoma in the era of immunotherapy: What comes next?
Authors: Ciro Celsa, Giuseppe Cabibbo, Marco Enea, Salvatore Battaglia, Giacomo Emanuele Maria Rizzo, Calogero Cammà
Journal: Journal of Clinical Oncology (2021)

324 Background: Atezolizumab plus Bevacizumab represents the new best performing first-line approach for unresectable hepatocellular carcinoma (u-HCC). However, the best sequential strategy after every first-line failure (for progression or intolerance) remains elusive, and options for retreating patients failing Atezolizumab plus Bevacizumab with multi-kinase inhibitors (MKI) or immune checkpoint inhibitor (ICI) are yet undefined. Methods: We developed a Markov model to analyze simulated-Overall Survival (s-OS) of second-line ICIs or MKIs after first-line Atezolizumab plus Bevacizumab over a lifetime horizon. For first-line therapy, PFS of Atezolizumab plus Bevacizumab was extracted from Imbrave 150 trial and it was used as endpoint since it is not influenced by post-progression survival. For second-line retreatment, pooled OS of MKIs (Regorafenib and Cabozantinib), or ICIs (Nivolumab and Pembrolizumab) were adopted. Survival estimates for sequential settings considered the proportion of patients who did not receive second-line therapy due to death during first-line therapy. Individual patient survival data were extracted from PFS and OS Kaplan-Meier curves of RESORCE trial for Regorafenib, CELESTIAL trial for Cabozantinib, CheckMate-040 for Nivolumab and Keynote-240 for Pembrolizumab. Each reconstructed survival curve was inspected for accuracy and was compared with originally published curves. Results: First-line Atezolizumab plus Bevacizumab followed by second-line ICIs turned on from the model as the best sequential strategy (median s-OS 24 months; 95% Confidence Interval (CI) 23-26 months) and extends survival when compared Atezolizumab plus Bevacizumab followed by MKIs (median s-OS 20 months; 95% CI 19-21 months). Conclusions: To our knowledge and given the absence of adequately designed sequential RCTs, this is the first model to date which suggests, with a proper methodological approach, an accurate estimate of outcome of patients with u-HCC treated by sequential systemic therapies. In patients with u-HCC failing first-line treatment, modelling estimates of s-OS for each retreatment strategies may assist in choosing the most promising sequences in order to plan appropriate RCTs.
Continuous Renal Replacement Therapy: The Interaction between Fluid Balance and Net Ultrafiltration
Authors: Thummaporn Naorungroj, Ary Serpa Neto, Raghavan Murugan, John A. Kellum, Rinaldo Bellomo
Journal: American Journal of Respiratory and Critical Care Medicine (2021)

"Continuous Renal Replacement Therapy: The Interaction between Fluid Balance and Net Ultrafiltration." American Journal of Respiratory and Critical Care Medicine, 203(9), pp. 1199–1201
The impact of multi-agent chemotherapy in metastatic pancreatic adenocarcinoma: A population-based study utilizing the SEER database.
Authors: Kavin Sugumar, Shreya Gupta, Jonathan J. Hue, Lee Mayer Ocuin, Luke Rothermel, Jeffrey Hardacre, John Brian Ammori, Jordan Michael Winter
Journal: Journal of Clinical Oncology (2021)

416 Background: Over the last decade, various landmark trials have demonstrated the impact of multi-agent chemotherapy in the treatment of PDAC. However, the impact in the ‘real world’ has been less clear. The ACCORD trial (2011) was a phase III trial comparing combination chemotherapy (FOLFIRINOX) and single agent (gemcitabine) for advanced disease. The MPACT trial introduced another beneficial regimen (nab-paclitaxel and gemcitabine) in 2013. Subsequently, multi-agent chemotherapy became standard of care for medically appropriate patients. Methods: We used the Surveillance, Epidemiology, and End Results (SEER) database to identify patients diagnosed with PDAC between 1998 and 2017. The cohort was divided into two groups: 1998-2011 (pre-ACCORD) and 2012-2017 (post-ACCORD). We analyzed all patients with metastatic PDAC for overall survival and compared results in the two groups using Kaplan Meier analysis and multivariate Cox proportional hazards models. An interrupted time series analysis was also used to compare the temporal trends in 2-year survival between 1998 and 2017. Results: A total of 47,134 patients were diagnosed with PDAC between 1998 and 2017. Nearly two-third of patients (26,438; 57%) had distant disease. On univariate survival analysis, there was a significant increased overall survival probability in the 2012-17 group compared to the 1998-2011 group (p&lt;0.05). The one- and two-year survival rates were 11% and 3% in the pre-ACCORD period compared to 14% and 4 % after the ACCORD trial respectively. This difference remained significant on multivariate analysis while adjusting for covariates (HR=0.08, 0.78-0.92, p=0.05). On interrupted time series analysis, we observed a steady rise in 2- year survival between 1998 and 2017. There was a significant jump in the two-year survival probability from 16% at 2011 to 20% at 2012 in metastatic PDAC (β=0.02, 0.009-0.03, p&lt;0.0001, Table). Conclusions: Beyond the randomized clinical trial arena, overall survival has increased over time, with a statistically significant jump around the time of the ACCORD trial. However, the absolute increase in the ‘real world’ is smaller than the gains observed in prospective clinical trials. [Table: see text]
Monocytes in the Tumor Microenvironment
Authors: Stefano Ugel, Stefania Canè, Francesco De Sanctis, Vincenzo Bronte
Journal: Annual Review of Pathology Mechanisms of Disease (2021)

Immunotherapy has revolutionized cancer treatment over the past decade. Nonetheless, prolonged survival is limited to relatively few patients. Cancers enforce a multifaceted immune-suppressive network whose nature is progressively shaped by systemic and local cues during tumor development. Monocytes bridge innate and adaptive immune responses and can affect the tumor microenvironment through various mechanisms that induce immune tolerance, angiogenesis, and increased dissemination of tumor cells. Yet monocytes can also give rise to antitumor effectors and activate antigen-presenting cells. This yin-yang activity relies on the plasticity of monocytes in response to environmental stimuli. In this review, we summarize current knowledge of the ontogeny, heterogeneity, and functions of monocytes and monocyte-derived cells in cancer, pinpointing the main pathways that are important for modeling the immunosuppressive tumor microenvironment.
Targeted Deep Sequencing in Untreated Progressive CLL Helps to Better Dissect the Genomic Landscape and Shows Novel Associations between Mutations, Prognostic and Clinical Parameters: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group
Authors: Esteban Braggio, Victoria Wang, Laura Ann Bruins, Santiago Barrio, Connie Lesnick, Jacqueline C. Barrientos, Susan M. O'Brien, Martin S. Tallman, Mark R. Litzow, Rafael Fonseca, Neil E. Kay, Tait D Shanafelt
Journal: Blood (2017)
Avoid Masks With Metal During Magnetic Resonance Imaging
Authors: Mary Chris Jaklevic
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Heart Rate Variability During the Week of September 11, 2001
Authors: Rachel Lampert
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy
Authors: Long Yuan, Jahnavi Tatineni, Kathleen M. Mahoney, Gordon J. Freeman
Journal: Trends in Immunology (2021)

V-domain Ig suppressor of T cell activation (VISTA) is a B7 family member that maintains T cell and myeloid quiescence and is a promising target for combination cancer immunotherapy. During inflammatory challenges, VISTA activity reprograms macrophages towards reduced production of proinflammatory cytokines and increased production of interleukin (IL)-10 and other anti-inflammatory mediators. The interaction of VISTA with its ligands is regulated by pH, and the acidic pH ~6.0 in the tumor microenvironment (TME) facilitates VISTA binding to P-selectin glycoprotein ligand 1 (PSGL-1). Targeting intratumoral pH might be a way to reduce the immunoinhibitory activity of the VISTA pathway and enhance antitumor immune responses. We review differences among VISTA therapeutics under development as candidate immunotherapies, focusing on VISTA binding partners and the unique structural features of this interaction.
AB0247 LIFE QUALITY AND DEPRESSION LEVEL ASSESSMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS
Authors: T. Janković, J. Zvekic-Svorcan, B. Milić, D. Vukliš, R. Krasnik, S. Subin
Journal: Annals of the Rheumatic Diseases (2020)

Background: Depression is a common and significant rheumatoid arthritis (RA) comorbidity that develops under the influence of severalfactors, the most important being disease activity, pain intensity and degree of disability. Objectives: The goal of the investigation was to determine existence of depression and assess life quality in patients living with RA. Methods: The study sample comprised of 150 patients of average age 59.2 years, 79.2% of whom were women and 20.8% were men, who have lived with RA for an average of 9.6 years. For determining disease activity level, Disease Activity ScoreDAS28was utilized. Pain intensity and global disease activity were rated using a visual analogue scale ranging from 1 to 100mm. For functional capacity assessments, Health Assessment Questionnaire(HAQ) index was adopted,depressions severity was determined through Back Depression Inventory (BDI), and Serbian version of the health-related quality of life instrument EQ-5Dwas employed to assess patients’ quality of life. Results: Average DAS28 score for the sample was4.46±1.32, suggesting moderate RA activity. Pain intensity was on average scored at 53.2±18.6, whereas global disease activity was measured at 49.63±20.2, and theHAQ indexof 1.0±0.70 was obtained. According to theBDI, 21.4% of the patients exhibited no signs of depression, whereas 12.9% had mild, 54.3% moderate, and11.4% severe form of depression.Quality of life, as measured by EQ-5D, was compromised in all life domains, withpain/discomfort, anxiety/depression, inability to partake in usual activities, compromised mobility and self-caremost frequently reported. In patients suffering from moderate and severe depression, high statistically significant positive correlation between depression score and HAQ index was noted.BDIscore was statistically significantly positively correlatedwith the ratings on the EQ-5D scales pertaining to self-care, usual activities, pain/discomfort, and anxiety/depression. Conclusion: Depression symptoms are common in patients with RA and can compromise quality of life in all life domains.When assessing disease severity and general status of patients with RA, depression symptoms should also be considered, given their high prevalence and influence on patients’ everyday life. Acknowledgments: not Disclosure of Interests: None declared
Individual socioeconomic status is important but hard to measure
Authors: Shona Kelly
Journal: BMJ (2021)

I was delighted to see Moscrop and colleagues’ article in an influential medical journal,1 as there is a desperate need for healthcare providers to collect social risk factors even if they can’t do anything about, for example, a person’s marital status. By some estimates, the non-clinical risk factors are of the same magnitude as all …
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial (vol 181, pg 32, 2021)
Authors: O. Hermine, X. Mariette, P. L. Tharaux, M. Resche-Rigon, R. Porcher, P. Ravaud, Corimuno Collaborative Grp
Journal: JAMA Internal Medicine (2021)
Direct-to-consumer genetic risk scoring for melanoma improves adherence to sun-protective behaviors among increased-risk groups: Results from a prospective United States cohort study
Authors: Xing Hu, James M. Kilgour, Alexander L. Fogel, Justin L. Jia, Prajakta D. Jaju, Jean Y. Tang, Kavita Y. Sarin
Journal: Journal of the American Academy of Dermatology (2021)
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial
Authors: Thomas Bachelot, Thomas Filleron, Ivan Bieche, Monica Arnedos, Mario Campone, Florence Dalenc, Florence Coussy, Marie-Paule Sablin, Marc Debled, Claudia Lefeuvre-Plesse, Anthony Goncalves, Marie-Ange Mouret Reynier, William Jacot, Benoit You, Philippe Barthelemy, Benjamin Verret, Nicolas Isambert, Xavier Tchiknavorian, Christelle Levy, Jean-Christophe Thery, Tifenn L’Haridon, Jean-Marc Ferrero, Alice Mege, Francesco Del Piano, Etienne Rouleau, Alicia Tran-Dien, Julien Adam, Amelie Lusque, Marta Jimenez, Alexandra Jacquet, Ingrid Garberis, Fabrice Andre
Journal: Nature Medicine (2021)
The elephant and the blind men: the children of long covid
Authors: Frances K Simpson, Amali U Lokugamage
Journal: BMJ (2021)

In response to Martinerie and colleagues’ article1 we note the concerns about the sociological effects of the pandemic on children. We feel, however, that the article’s view that SARS-CoV-2 infection is less severe in children is unsubstantiated and, as outlined in our BMJ Opinion piece,2 there has been insufficient epidemiological study …
Treatment by CRISPR-Cas9 Gene Editing — A Proof of Principle
Authors: Harry L. Malech
Journal: New England Journal of Medicine (2021)

As a tool of great promise for the treatment of inherited human diseases, the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease system has captured public imagination, with its precision and versatility being likened to genetic scissors and the letter-by-letter editing capabilities of word-processing software.1 No longer hypothetical, CRISPR-Cas9 is producing exciting results for medical teams. As described in this issue of the Journal, Frangoul and colleagues2 have used the gene-editing technology to achieve a remarkable level of functional correction of the disease phenotype in two transfusion-dependent patients with either β-thalassemia or sickle cell disease by alleviating the severe anemia . . .
Compression Garment Reduces Orthostatic Tachycardia and Symptoms in Patients With Postural Orthostatic Tachycardia Syndrome
Authors: Kate M. Bourne, Robert S. Sheldon, Juliette Hall, Matthew Lloyd, Karolina Kogut, Nasia Sheikh, Juliana Jorge, Jessica Ng, Derek V. Exner, John V. Tyberg, Satish R. Raj
Journal: Journal of the American College of Cardiology (2021)
Abstract 10573: Epigenetic Analyses of Human Left Atrial Tissue Identifies Gene Networks Underlying Atrial Fibrillation
Authors: Amelia W Hall, Nathan R Tucker, Mark Chaffin, Carolina Roselli, Honghuang Lin, Valerio Bianchi, Geert Geeven, Kenneth C Bedi, Kenneth Margulies, Wouter De Laat, Patrick T Ellinor
Journal: Circulation (2019)

Introduction: Atrial fibrillation (AF) often arises from dysfunction in the left atrium (LA), a tissue with limited annotation of the non-coding genome and its effects on gene expression. As many A...